What is your background dealing with metabolic disorders?

What are your initial impressions on IONS obesity drug based on how it performed in Phase 1? What would you expect to see in the Phase 2a data?

Are there any alternative types of obesity treatment you see as more viable (other than exercise)?

Are there any competitors to Ionis you're aware of that may be flying under the radar? How do you see them as a threat?

IONS had two phase 3 trial concerns this year and a huge stock plunge as a result (the drugs may have caused severely depressed platelet counts). Does this have any implications on how you see IONIS-FGFR4Rx performing?

Some analysts have suggested IONS could have trouble getting drugs to market due to its platelet related financial troubles. Are metabolic drugs like IONIS-FGFR4Rx ypically more or less expensive to develop? Do you see this drug as promising enough to attract buyer's for the company?